Multispectral and Hyperspectral Preclinical Imager Spanning the Visible, NIR-I and NIR-II

项目总结/摘要 这是来自工程学院、艺术与科学学院和 波士顿大学（BU）萨金特学院请求购买用于光致发光的临床前成像仪 和生物发光。虽然波士顿大学的研究人员广泛使用基于光的 光学成像，主要是先进的显微镜技术在校园以及校外的体内成像 系统，目前还没有在BU查尔斯河校区的整体动物成像能力。收购 临床前成像仪将使研究人员能够推进他们的NIH资助的研究计划， 对复杂完整的哺乳动物系统的研究用户建议购买第一个上市的 成像器，这将使传统的荧光和生物发光成像在可见光和第一近 红外（NIR-I）光学组织窗口波长范围（分别为500 - 650 nm和650 - 900 nm 短波红外（SWIR，也称为第二NIR光学组织窗口或NIR-II）成像。通过使用 在1000 - 1700 nm范围内的光，实现更深的穿透深度，具有更少的光散射，导致 前所未有的清晰度在组织深度光基成像。通过设计一个定制的工具来涵盖这一点， 扩展波长范围，BU研究人员将能够继续目前的研究方向， 在传统的成像更快，更方便地使用本地，校园内的设备，同时也加快 资助开发短波红外造影剂，并使未来的方向使用短波红外成像， 超出了该地区任何研究人员公开获得的范围。 拟议仪器的用户有各种各样的研究兴趣。建议的应用 临床前成像仪通常专注于使用生物发光跟踪工程化细胞， 肿瘤和脉管系统与外源性造影剂，和纳米药物的纳米粒子的跟踪 应用. 在本提案中，我们描述了我们旨在获得的工具，该特定工具的优势， 其他，提供了一个管理计划，仪器的使用和成本回收，并说明了机构 致力于维护这一资源。总的来说，收购这款临床前成像仪将支持项目 重点是改善人类健康和疾病治疗的各个方面。

Project Summary/Abstract This is a proposal from ten investigators from the College of Engineering, the College of Arts and Sciences and Sargent College at Boston University (BU) requesting purchase of a preclinical imager for photoluminescence and bioluminescence in mice. While the researchers at Boston University make extensive use of light-based optical imaging, primarily with advanced microscopy techniques on campus as well as off-campus in vivo imaging systems, there currently is no whole animal imaging capability on the BU Charles River Campus. Acquisition of a preclinical imager will allow the researchers to advance their NIH funded research programs that depend on the examination of complex, intact mammalian systems. The users propose the purchase of a first-to-market imager that will enable both traditional fluorescence and bioluminescence imaging in the visible and first near infrared (NIR-I) optical tissue window wavelength ranges (500 – 650 nm and 650 – 900 nm, respectively) as well as shortwave infrared (SWIR, also known as the second NIR optical tissue window or NIR-II) imaging. By using light in the 1000 – 1700 nm range, deeper penetration depths are achieved with less light scattering, leading to unprecedented clarity in tissue-depth light-based imaging. By designing a customized instrument to cover this extended wavelength range, the BU researchers will be able to continue current research directions that depend on traditional imaging more quickly and conveniently using local, on-campus equipment, while also hastening the funded development of SWIR contrast agents and enabling future directions using SWIR imaging that are beyond what is openly available to any researcher in the region. The users for the proposed instrument have a diversity of research interests. The proposed applications of the preclinical imager are typically focused on the tracking of engineered cells using bioluminescence, the imaging of tumors and vasculature with exogenous contrast agents, and the tracking of nanoparticles for nanomedicine applications. In this proposal, we describe the instrument we aim to acquire, the benefits of this particular instrument over others, provide a management plan for instrument use and cost recovery, and illustrate the institutional commitment to maintaining this resource. Overall, the acquisition of this preclinical imager will support projects focused on improving diverse aspects of human health and the treatment of disease.